SCHEMBL6527443

SCHEMBL6527443

COc1ccc(-c2nc3ccc(-c4ccc(F)c(CO)c4F)cn3c2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.47
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MAPT P10636 3/20 0.42
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RAB9A P51151 2/20 0.41
NR1H4 Q96RI1 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.39
ALOX5 P09917 1/20 0.39
ATM Q13315 2/20 0.39
SLC2A1 P11166 2/20 0.39
TSPO P30536 1/20 0.38
PSMD14 O00487 1/20 0.37
MMP2 P08253 1/20 0.37
TUBB4A P04350 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6520541 0.88 NR4A2 (0.61) NR4A2CYP11B1CYP11B2MAPTGAA
SCHEMBL6519571 0.88 NR4A2 (0.50) NR4A2CYP11B1CYP11B2MAPTKDM4E
SCHEMBL6523033 0.88 CYP11B1 (0.44) CYP11B1CYP11B2MAPTGAAKDM4E
SCHEMBL6521387 0.82 NR4A2 (0.51) NR4A2CYP11B1CYP11B2MAPTRAB9A
SCHEMBL3431629 0.80 NR4A2 (0.46) NR4A2GAANR1H4SLC2A1
SCHEMBL2065205 0.79 NR4A2 (0.76) NR4A2MAPTGAAKDM4EALDH1A1
SCHEMBL16208077 0.78 NR4A2 (0.65) NR4A2MAPTGAAALDH1A1MEN1
SCHEMBL3431442 0.77 NR4A2 (0.47) NR4A2MAPTGAAALDH1A1NR1H4
SCHEMBL6524183 0.76 DHODH (0.44) CYP11B1CYP11B2MAPTKDM4EALDH1A1
SCHEMBL6523534 0.73 SLC2A1 (0.39) NR4A2CYP11B1CYP11B2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP claimed
EP-2262769-B1 POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-11-05 EP disclosed
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065745-A1 POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF JAK2, ABL1, REN NR4A2 1394/4885CYP11B1 30/4885CYP11B2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.